TOP STORIES

• REGULATORY Government’s Pharma Innovation Panel to Propose Comprehensive Upgrades in Industry Policies
  May 17, 2024

• REGULATORY First Innovation Premium in 6 Years Axed for Sargmalin, “Zero” Rule Hits Yet Again
  May 16, 2024

• REGULATORY Chuikyo OKs Listing of 18 Meds, All Get Price Premiums; Biggest Peak Sales for Beyfortus
  May 16, 2024

• REGULATORY Alexion Takes Hit from 1st Market Expansion Re-Pricing of Ultomiris, Soliris
  May 16, 2024

• REGULATORY BMS’s Sotyktu to Get 8.6% Price Cut in August after Cost-Effectiveness Assessment
  May 16, 2024

• REGULATORY Annual Price Revisions Should Continue in 2025 and Beyond: MOF Budget Examiner
  May 15, 2024

• BUSINESS As Latuda Sales Evaporate, Sumitomo Shakes Up Top Brass for Turnaround
  May 15, 2024

• BUSINESS Teva to Let Go of Japan Generic Business in 2025 but Denies Full Exit
  May 15, 2024

• ACADEMIA Researchers Crafting Japan’s 1st Guidelines for ALS Trials, Eye FY2026 Completion
  May 14, 2024

• BUSINESS Lilly’s Gemzar to Exit Japan Market Next Spring under G1 Withdrawal Rule
  May 13, 2024

• BUSINESS Moderna Set to Develop Cancer Vaccines, Rare Disease Therapies in Japan: New Local Chief
  May 10, 2024

• BUSINESS Lilly Japan Nets 10% Sales Rise in 2023, Eyes No. 1 Growth for Protected Medicines
  May 9, 2024

• BUSINESS Lilly Files Tirzepatide for Obesity in Japan, Ties Up with Mitsubishi
  May 9, 2024

• ACADEMIA Japan to Forge National Registry for Leqembi, Test Genes to Predict Side Effects
  May 8, 2024

• REGULATORY New LDP Project Team Boots Up for Healthcare Transformation
  May 8, 2024

• BUSINESS Jevtana Supply Crunch amid Demand Spike Already Affecting Patients in Japan
  May 7, 2024

• BUSINESS Sumitomo Sets Out for Reconstruction, Further Cost Cuts in FY2024
  May 2, 2024

• BUSINESS Regeneron Set for Commercial Expansion in Japan, Eyes Dupixent Ramp-Up
  May 1, 2024

• BUSINESS Celltrion Japan Unveils New List of 5 Biosimilars in Development; Actemra and Pralia and More
  May 1, 2024

• REGULATORY Japan’s 1st Eylea Biosimilar Now in Line for Approval, AMD Dropped for Patent Reasons
  April 30, 2024

ページ

• « 先頭
• ‹ Prev
• …
• 27
• 28
• 29
• 30
• 31
• 32
• 33
• 34
• 35
• …
• Next ›
• 最終 »